These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 31335691

  • 21. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M, Kitajima K, Toriihara A, Arigami T, Daisaki H, Nakamura A, Ohtsuka T, Miwa H, Yoshiura T.
    Medicine (Baltimore); 2021 Apr 16; 100(15):e25494. PubMed ID: 33847661
    [Abstract] [Full Text] [Related]

  • 22. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
    Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, Fuereder T, Fabikan H, Fazekas A, Schwab S, Mayerhoefer ME, Herold C, Prosch H.
    Clin Nucl Med; 2019 Jul 16; 44(7):535-543. PubMed ID: 31021918
    [Abstract] [Full Text] [Related]

  • 23. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.
    Kim JE, Chae SY, Kim JH, Kim HJ, Kim TW, Kim KP, Kim SY, Lee JL, Oh SJ, Kim JS, Ryu JS, Moon DH, Hong YS.
    Eur J Nucl Med Mol Imaging; 2019 Jul 16; 46(8):1713-1722. PubMed ID: 31041456
    [Abstract] [Full Text] [Related]

  • 24. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 16; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 25. Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
    Sachpekidis C, Larribère L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A.
    Cancer Immunol Immunother; 2019 Feb 16; 68(2):297-303. PubMed ID: 30478475
    [Abstract] [Full Text] [Related]

  • 26. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 16; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 27. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18F-FDG PET/CT with Conventional CT.
    Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, Jensen JD, Asmussen JT, Jylling AMB, Braad PE, Vach W, Ewertz M, Hildebrandt MG.
    J Nucl Med; 2023 Mar 16; 64(3):355-361. PubMed ID: 36207136
    [Abstract] [Full Text] [Related]

  • 28. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.
    Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Mar 16; 45(3):376-383. PubMed ID: 29124281
    [Abstract] [Full Text] [Related]

  • 29. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 30. The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria.
    Sachpekidis C, Weru V, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2023 Jul 05; 50(9):2699-2714. PubMed ID: 37099131
    [Abstract] [Full Text] [Related]

  • 31. Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study.
    Hribernik N, Strasek K, Huff DT, Studen A, Zevnik K, Skalic K, Jeraj R, Rebersek M.
    Radiol Oncol; 2024 Sep 01; 58(3):335-347. PubMed ID: 39287171
    [Abstract] [Full Text] [Related]

  • 32. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F.
    J Nucl Med; 2020 Jul 01; 61(7):990-998. PubMed ID: 31806768
    [Abstract] [Full Text] [Related]

  • 33. FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
    Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD.
    Clin Cancer Res; 2024 May 01; 30(9):1758-1767. PubMed ID: 38263597
    [Abstract] [Full Text] [Related]

  • 34. Clinical and Prognostic Value of 18F-FDG-PET/CT in the Restaging Process of Recurrent Cutaneous Melanoma.
    Albano D, Familiari D, Fornito MC, Scalisi S, Laudicella R, Galia M, Grassedonio E, Ruggeri A, Ganduscio G, Messina M, Spada M, Midiri M, Alongi P.
    Curr Radiopharm; 2020 May 01; 13(1):42-47. PubMed ID: 31595860
    [Abstract] [Full Text] [Related]

  • 35. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    Castello A, Toschi L, Rossi S, Mazziotti E, Lopci E.
    J Cancer Res Clin Oncol; 2020 May 01; 146(5):1235-1243. PubMed ID: 32048008
    [Abstract] [Full Text] [Related]

  • 36. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV.
    Lancet Oncol; 2021 Jun 01; 22(6):836-847. PubMed ID: 33989557
    [Abstract] [Full Text] [Related]

  • 37. 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma.
    Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, Herschtal A, Fullerton S, Milne D, Iravani A, McArthur GA, Hicks RJ.
    Cancer Imaging; 2020 May 14; 20(1):36. PubMed ID: 32408884
    [Abstract] [Full Text] [Related]

  • 38. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K, Nielsen D, Jensen BV, Hendel HW.
    J Nucl Med; 2013 Jul 14; 54(7):1026-31. PubMed ID: 23572497
    [Abstract] [Full Text] [Related]

  • 39. Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review.
    Bisschop C, de Heer EC, Brouwers AH, Hospers GAP, Jalving M.
    Crit Rev Oncol Hematol; 2020 Sep 14; 153():103044. PubMed ID: 32673997
    [Abstract] [Full Text] [Related]

  • 40. Clinical Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer.
    Hynninen J, Laasik M, Vallius T, Kemppainen J, Grönroos S, Virtanen J, Casado J, Hautaniemi S, Grenman S, Seppänen M, Auranen A.
    Clin Oncol (R Coll Radiol); 2018 Aug 14; 30(8):507-514. PubMed ID: 29753662
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.